Azithromycin 3 days
ApprovedSmall molecule
Azithromycin 3 days is one of 6 small molecule programs targeting Scrub Typhus. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Scrub Typhus
#DrugCompanyPhaseTrials
1Ketek
SanofiPhase 3
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Doxycycline 7 Days
UUniversity Medical Centre Ljubljana
Approved
Azithromycin 3 days
UUniversity of Oxford
Approved
Doxycycline 3 Days
UUniversity of Oxford
Approved
Rifadin
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Azithromycin 3 days. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity of Oxford